"And beyond the time and cost savings, Datawatch has accelerated our ability to gather data. Our business processes will be improved thanks to our ability to automate the capture of instrument data, speed the flow of business information, and meet quality & regulatory requirements much more easily," Mushtaq added."Binding Site is the perfect example of how organizations can drive efficiencies, save money and improve regulatory compliance and auditing with automation. While other companies spend up to 80 percent of their analysts' time on data preparation, typically with many errors, Binding Site is quickly transforming raw information into reliable, consistent data sets ready for data analysis and reporting," said Dan Potter, chief marketing officer at Datawatch. About Binding Site Binding Site is committed to improving patient lives worldwide through education, collaboration and innovation. The company focuses on research, development, manufacture and distribution of innovative immunodiagnostic systems and assays for the global laboratory market. By utilizing its specialized expertise in antibody specificity technology, Binding Site has developed a broad menu of special protein assays, including the Freelite® test, the only FDA cleared and guideline-recommended serum free light chain assay on the market. Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of those patients with specific cancers and immune disorders. About Datawatch Corporation Datawatch Corporation (NASDAQ-CM: DWCH) enables ordinary users to deliver extraordinary results with all their data. Only Datawatch can unlock data from the widest variety of sources and prepare it for use with visualization tools or other business processes. When real-time visibility to rapidly changing data is critical, Datawatch enables you to visualize streaming data for the most demanding business environments such as capital markets. Organizations of every size worldwide use Datawatch products including 93 of the Fortune 100. Datawatch is headquartered in Bedford, Massachusetts with offices in New York, London, Frankfurt, Stockholm, Singapore, and Manila, and with partners and customers in more than 100 countries worldwide. See how Datawatch can help you by downloading a free version at www.datawatch.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any such statements contained herein, including but not limited to those relating to product performance and viability, are based on current expectations, but are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations. The factors that could cause actual future results to differ materially from current expectations include the following: rapid technological change; Datawatch's dependence on the introduction of new products and product enhancements and possible delays in those introductions; acceptance of new products by the market, competition in the software industry generally, and in the markets for next generation analytics in particular; and Datawatch's dependence on its principal products, proprietary software technology and software licensed from third parties. Further information on factors that could cause actual results to differ from those anticipated is detailed in various publicly-available documents, which include, but are not limited to, filings made by Datawatch from time to time with the Securities and Exchange Commission, including but not limited to, those appearing in the Company's Annual Report on Form 10-K for the year ended September 30, 2015. Any forward-looking statements should be considered in light of those factors.
© 2016 Datawatch Corporation. Datawatch and the Datawatch logo are trademarks or registered trademarks of Datawatch Corporation in the United States and/or other countries. All other names are trademarks or registered trademarks of their respective companies.
Investor Contact: Datawatch Investor Relations email@example.comPhone: (978) 441-2200 ext. 8323Media Contact: Sarah BernardiDatawatch CorporationSarah_Bernardi@datawatch.comPhone: (978) 441-2200 ext. 8387Twitter: @datawatch